GLP-1 Adherence
8 articles on GLP-1 Adherence, researched and written by the Shotlee Editorial Team from primary sources.
GLP-1 Weight Loss: Why Consistency Matters for Ozempic & Wegovy
Recent preclinical research suggests that inconsistent use of GLP-1 medications like Ozempic and Wegovy may diminish their effectiveness over time. Discover the science behind adherence and how to optimize your therapy.
9 min read
Quitting GLP-1s Like Ozempic? Many Plan to Restart Despite Risks
Many patients start GLP-1 medications like Ozempic and Zepbound for obesity but quit within a year, with fewer than one in four remaining on treatment. Shockingly, 74% of those who stop plan to restart, despite experts warning against this cycling approach. This guide explores the data, risks like muscle loss, and what it means for your health.
5 min read
New GLP-1 Playbook for Weight Loss: Shots to Pills Shift
Weight loss treatment is evolving with a new GLP-1 playbook: start with weekly injections for rapid results, then transition to convenient pills for maintenance. Eli Lilly's weight-loss tablet and oral Wegovy promise easier adherence, but with trade-offs in effectiveness and strict dosing rules. Doctors highlight the maintenance challenges that make this shift essential.
6 min read
Grim Effects of Stopping GLP-1s Like Ozempic, Study Reveals
New research paints a grim picture: stopping GLP-1 drugs like Ozempic can rapidly reverse cardiovascular benefits, with risks spiking 8% after just six months. A Washington University study of over 333,000 patients highlights the 'metabolic whiplash' of discontinuation. Understand the findings and why adherence matters.
5 min read
GLP-1 Persistence for Weight Loss Nearly Doubles in Recent Years
Persistence rates for GLP-1 medications like semaglutide and tirzepatide in patients without diabetes seeking weight loss have nearly doubled over the past five years, jumping from 33.2% in 2021 to 60.9% in mid-2024. New research highlights improved adherence, the role of drug switching, and factors like resolved supply shortages driving these gains. These trends offer hope for long-term obesity management.
5 min read
Babson Fingertip Blood Tests Now Include GLP-1 Monitoring
Babson Diagnostics, crowned Medtech Company of the Year in 2024, now offers GLP-1 monitoring through its innovative fingertip blood tests. Patients on GLP-1 medications like Wegovy can pick up prescriptions and get comprehensive bloodwork in one pharmacy stop. This pea-sized sample panel tracks key metrics for safer, more effective therapy.
7 min read
Should Employers Cover GLP-1 Drugs? 4 Key Facts to Consider
The launch of the first oral GLP-1 weight-loss drug, Wegovy pill, is sparking renewed interest among employees wary of injections. But as demand surges, employers face tough choices on coverage amid high costs and side effects. This guide outlines 4 key facts from industry experts to inform your benefits strategy.
6 min read
States Step In to Make Obamacare Plans More Affordable After Subsidy Expiration
With federal Obamacare subsidies expired, premiums have surged, but ten states are stepping in with their own aid to keep coverage affordable. New Mexico fully replaces the gap for all incomes, while others target low earners amid cost pressures from GLP-1 drugs like Ozempic and Wegovy. Enrollment trends vary, with some states seeing gains despite national drops.
6 min read